Posterior Chamber Phakic Intraocular Lens Implantation in Eyes with an Anterior Chamber Depth of Less Than 3 mm: A Multicenter Study.

This study was aimed to assess the clinical outcomes of Visian ICL (hole ICL; STAAR Surgical, Inc.) implantation for the correction of myopic refractive errors in eyes having an anterior chamber depth (ACD) below the current manufacturer's recommendation (<3.0 mm). We comprised 365 eyes of 201 consecutive patients (mean age ± standard deviation, 35.7 ± 7.5 years) with spherical equivalents of -8.66 ± 3.54 D. We evaluated the safety, efficacy, predictability, stability, intraocular pressure (IOP), endothelial cell density (ECD), and complications. The safety and efficacy indices were 1.12 ± 0.22 and 0.98 ± 0.22. At 1 year, 90% and 98% of eyes were within ± 0.5 and 1.0 D of the attempted correction, respectively. Changes in the manifest refraction from 1 week to 1 year postoperatively were -0.08 ± 0.34 D. The mean ECD loss was 0.2 ± 8.7%. No eyes showed a significant ECD loss (≥30%). We found no significant correlation between the ACD and the change in ECD (Pearson correlation coefficient r = -0.048, p = 0.360). No significant IOP rise or vision-threatening complication occurred at any time. These findings indicate that the surgical indication of ICL implantation should be reconsidered in terms of ACD.